YBL-013

N/A

Report date: 2026/03/19 17:01:33

Base Information

Drug NameYBL-013
Drug Alias NamePDL1-ALiCEACE-005Bite-005YBL-013ACE-05 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionProgrammed death-ligand 1 blockersAnti-CD3
TargetsProgrammed death-ligand 1T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesY-biologics Inc
China Registration ClassN/A

Develop Information

Active Companies3d Medicines IncY-biologics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A